Navigation Links
Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Date:7/9/2013

BURLINGTON, Mass., July 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European oncologists indicate that overall survival is the factor that most influences their prescribing decisions for unresectable malignant melanoma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought-leaders are optimistic that Bristol-Myers Squibb/Ono Pharmaceuticals' nivolumab and GlaxoSmithKline's Tafinlar plus GlaxoSmithKline's Mekinist, in particular, will show advantages over sales-leading ipilimumab (Bristol-Myers Squibb's Yervoy) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled As Vemurafenib and Ipilimumab Gain Traction in the Market, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? finds that surveyed U.S managed care organization (MCO) pharmacy directors demand that emerging therapies provide significant improvements in overall survival over vemurafenib (Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf) to justify their cost and secure reimbursement. Vemurafenib is the premium-priced standard-of-care in unresectable malignant melanoma patients harboring the V600 BRAF mutation. Notably, a third of surveyed payers would not reimburse a new therapy priced the same as vemurafenib or higher that offers a six-month improvement in overall survival over vemurafenib, citing insufficient overall clinical benefit as one of the key reasons for not granting reimbursement.

The report also finds that surveyed U.S. and European oncologists identified hematological toxicity as the safety and tolerability attribute that is most important when making prescribing decisions in unresectable malignant melanoma, thus indicating the persisting high level of unmet need for therapies with a more favorable hematological profile.

"Despite the improvements effected by vemurafenib and ipilimumab on patient overall survival in unresectable malignant melanoma, our survey results suggest that both physicians and MCO pharmacy directors have high expectations of the requirements of emerging therapies to further extend survival," said Decision Resources Business Insights Analyst Samuel Mentzer, M.Sc. "Early-stage clinical data suggest that Tafinlar in combination with Mekinist and nivolumab have the potential to gain a competitive edge over ipilimumab and vemurafenib if they can replicate these promising results in their ongoing Phase III trials."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
4. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
5. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
6. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
7. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
8. Effectively Bringing Fixed Dose Combination Products to Market to Maintain Growth and Pipelines
9. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
10. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... ... global chromatography market to grow at a CAGR of 5.42% during the ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/8/2016)... 8, 2016  Economic growth in the United States ... supply management executives in their December 2016 Semiannual Economic ... recovery that began in mid-2009, as indicated in the ... ® . The manufacturing sector is optimistic about growth ... manufacturing industries, and the non-manufacturing sector indicates that 14 ...
Breaking Medicine Technology:
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... ... 2016 , ... STAT courier is pleased to announce that due to customer ... are expanding their presence in Dallas. One of the most exciting parts for STAT ... to the Dallas and Forth Worth market. STAT takes pride in treating their employees ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Vida ... an $18M Series B led by Canvas Ventures . Other investors include Nokia ... scale its mobile platform to serve more consumers who are managing chronic conditions ...
Breaking Medicine News(10 mins):